- **Return to Growth**: Q3 2025 marks return to organic growth with 1.6% QoQ increase, driven by core therapies and strategic partnerships.
- **Strategic Acquisitions**: $17M-$18M joint venture with Hart Medical adds $60M annualized revenue, embedding into 3 major health systems.
- **Operational Resilience**: 23.5% EBITDA margin maintained despite 4.1% YoY revenue decline, supported by recurring revenue (81% of total).
- **Expansion into Michigan**: New market entry with 29 locations and 67,000 monthly patients, aligning with aging population and chronic disease trends.
- **Margin Improvement Plan**: Targeting EBITDA margin expansion through operational integration and cost efficiency in acquisitions.

**【CEO Opening Remarks】**
- **Revenue Stabilization**: Q3 2025 revenue stabilized at $58.3 million, with a 1.6% QoQ organic growth, driven by core therapies and sleep resupply recovery.
- **Strategic Partnerships**: Announced a joint venture with Hart Medical Equipment, adding $60 million in annualized revenue and embedding into 3 major health systems' discharge pathways.
- **Operational Efficiency**: Adjusted EBITDA margin of 23.5%, consistent with prior quarters, reflecting structural improvements since late 2024.
- **Market Expansion**: Entered Michigan and Ohio, expanding to 160 locations across 27 states, serving 325,000 active patients.

**【CFO Financial Commentary】**
- **Revenue Performance**: Q3 2025 revenue decreased 4.1% YoY to $58.3 million, but 81% of revenue was recurring, showing resilience.
- **Profitability**: Adjusted EBITDA of $13.7 million (23.5% margin), with a 7.7% YoY decline in 9-month EBITDA due to higher CapEx for ventilator replacements.
- **Liquidity**: $11.3 million cash on hand, with $35.3 million credit availability, supporting $6.6 million annualized revenue from the Ballad Health acquisition.
- **Cost Management**: Operating expenses as a percentage of revenue rose to 53.3% (from 50.4% YoY), driven by patient care CapEx increases.

**【CEO Continued Remarks】**
- **Product Innovation**: Introduced a new Medicare-approved respiratory device for high-acuity patients, aligning with aging population trends.
- **Sales Growth**: Launched the Quipt Sales Academy to accelerate onboarding and improve referral conversion rates.
- **Sleep Business Momentum**: GLP-1 drug use linked to 300-500 basis point increases in CPAP resupply adherence, supporting sleep care demand.

**【Q&A Highlights】**
- **EBITDA Margin Target**: Hardik Mehta emphasized maintaining or expanding EBITDA margins through expense stabilization and revenue growth.
- **JV Integration**: Greg Crawford stated Hart Medical's EBITDA margin will align with Quipt's average within 3 quarters via operational best practices.
- **M&A Pipeline**: CEO noted a strong pipeline of health system-aligned acquisitions, with a focus on scalable partnerships.
- **Policy Impact**: No anticipated impact from the One Big Beautiful Bill on current operations.


Quipt Home Medical Corp. (QIPT) Q3 2025 Earnings Call Transcript

- **Q2 2025 Results**: Revenue $57.4M (-6% YoY), Adjusted EBITDA $13.4M (23.3% margin). Challenges: Humana attrition, contract loss, seasonal lows.
- **Strategic Priorities**: Healthcare system partnerships, operational efficiency, NCIB share buybacks.
- **Philips Recall**: CapEx delays expected to resolve by Q3/Q4, impacting cash flow temporarily.
- **Positive Trends**: April shows rental and supply recovery; Q3/Q4 growth momentum expected.

**【CEO Opening Remarks】**
- Quipt Home Medical operates 130+ locations across 26 states, serving 223,000 active patients, with 75% of product mix in respiratory care. Q2 2025 revenue declined 6% YoY to $57.4M due to patient attrition from a capitated agreement loss, un-renewed disposable supply contract, and seasonal resupply lows. Adjusted EBITDA margin remained strong at 23.3% despite revenue softness. Key priorities: returning to organic growth, optimizing capital allocation (active NCIB), and healthcare system partnerships.

**【CFO Financial Commentary】**
- Q2 2025: Revenue $57.4M (-6% YoY), Adjusted EBITDA $13.4M (23.3% margin), Net Loss $3M. Six-months: Revenue $118.8M (-4% YoY), Adjusted EBITDA $27.4M (-10.4% YoY). Cash flow from operations $18.3M, liquidity $30.7M, net debt/EBITDA 1.5x. Margins protected via operational efficiency initiatives (back-office streamlining, logistics optimization).

**【CEO Additional Remarks】**
- Q2 challenges included Humana MA member attrition and contract non-renewal, but April trends show stabilization in rental and supply revenue. Strategic focus on healthcare system partnerships (preferred provider agreements) to embed in hospital discharge processes. Operational improvements include simplified processes and centralized support functions. Philips ventilator recall causing CapEx delays, expected to resolve by Q3/Q4.

**【Q&A Highlights】**
- **Humana Impact**: Referral behavior from Humana PPO plans caused unexpected attrition. **Disposable Contract**: Non-renewal in Q4 2024 reduced Q2 revenue. **Cash Flow**: Philips recall delays and timing of CapEx payments impacted Q2 cash flow, but trends stabilizing. **Growth Engine**: April data shows rental and supply recovery, with Q3/Q4 expected to show momentum. **Cost of Goods**: Year-to-date stable at 27.9%, future improvements expected.

Quipt Home Medical Corp. (QIPT) Q2 2025 Earnings Call Transcript

- **Stable Q1 Performance**: $61.4M revenue, 22.8% EBITDA margin, despite $8M headwinds from contract terminations. 
- **Sleep Business Resilience**: GLP-1 meds boost PAP therapy adherence by 10.7%, supporting 77% recurring revenue mix. 
- **Cost Optimization**: Sequential EBITDA up 4.5%, net leverage at 1.5x, $15.5M cash on hand. 
- **Growth Path**: 2% QoQ organic growth target, 25% EBITDA margin achievable with scale, Medicare rate reinstatement could add $3M/year. 


**【CEO Opening Remarks】**
- Q1 2025 revenue of $61.4M, stable QoQ, with 22.8% adjusted EBITDA margin ($14M). 
- 77% of revenue from respiratory care, driven by aging population and chronic disease trends. 
- Sleep business resilient despite GLP-1 med impact, with 10.7% higher PAP therapy adherence in 1.2M patient study. 
- Operational efficiency initiatives reduce costs, net leverage at 1.5x. 

**【CFO Financial Highlights】**
- 3% YoY increase in unique setups (221K vs 215K), 1% growth in resupply setups (124K). 
- Revenue decline due to Medicare 75-25 rate discontinuation (-$3M) and contract terminations (-$8M annualized). 
- Sequential EBITDA improvement (4.5%) from cost optimization, 77% recurring revenue mix. 
- Cash flow of $9.3M, $15.5M cash on hand, and $47.9M liquidity. 

**【Q&A Key Takeaways】**
- Contract termination headwinds: $2.5M annualized for disposable supplies, $1M/Q2 and $0.7M/Q3 from Humana PPO losses. 
- 25% EBITDA margin target achievable with scale, but not in 2025. 
- Resupply growth (174K patients) via improved catchment rates (>80%) and compliance tracking. 
- Organic growth target of 2% QoQ to return to 8-10% annual growth. 
- Medicare 75-25 rate reinstatement could add $3M annual revenue. 
- Bad debt expense ~4.5%, expected to decline with RCM improvements. 


Actual	0.19	-0.035	-0.06	0.14	0	0.05	0.01	-0.02	-0.03	-0.03	-0.01	-0.03	-0.04	-0.08	-0.03	-0.07	-0.07	-0.08	-0.1
Forecast	0.0332	-0.0238	0.0244	0.0047	0.03	0.02	-0.0209	0.031	-0.0017	-0.0017	-0.015	0.0067	-0.008	-0.0182	-0.0421	-0.0155	-0.0686	-0.0317	-0.1
Surprise	+472.29%	-47.06%	-345.90%	+2878.72%	-100.00%	+150.00%	+147.85%	-164.52%	-1664.71%	-1664.71%	+33.33%	-547.76%	-400.00%	-339.56%	+28.74%	-351.61%	-2.04%	-152.37%	0.00%

QIPT(Delisted)

QIPT fundamentals

QIPT Q1 2026 Earnings

Earnings Call

You can ask Aime